Study Assessing the Safety and Efficacy of ABT-263 in Subjects With B-cell Chronic Lymphocytic Leukemia (CLL) Who Have Failed at Least One Prior Fludarabine-containing Regimen

B-cell Chronic Lymphocytic Leukemia Clinical Trial

Official title:

A Phase 2b Monotherapy Study of ABT-263 in Subjects With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT00918450
• Other study ID #: M10-738
• Status: Withdrawn
• Phase: Phase 2
• First received: May 22, 2009
• Last updated: February 25, 2010
• Start date: March 2010

Study information

• Verified date: February 2010
• Source: Abbott
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This is a Phase 2b, open-label, multicenter, global study assessing the safety and efficacy of ABT-263 in subjects with B-cell CLL who have failed at least one prior fludarabine-containing regimen.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 150
• Est. primary completion date: December 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• >= 18 yrs of age, have B-cell CLL, failed at least 1 prior fludarabine-containing regimen.

• Refractory to 1 fludarabine-containing regimen is defined as failure to achieve at least PR to the last fludarabine-containing regimen received, or disease progression while receiving the last fludarabine-containing regimen, or disease progression in responders (i.e., achieved a PR or CR) within 6 mos of the last cycle of the last fludarabine-containing regimen received (e.g., fludarabine monotherapy, FR, or FC) or in responders (i.e., achieved a PR or CR ) within 24 mos of the last cycle of FCR.

• Intolerant to fludarabine is defined as discontinuation of therapy within 2 cycles due to side effects/toxicity from the last fludarabine-containing regimen.

• ECOG score of <=1.

• Adequate coagulation, renal, & hepatic function at Screening as follows:

• Serum creatinine <= 2.0 mg/dL or calculated creatinine clearance >= 50 mL/min;

• AST & ALT <= 3.0 x ULN;

• Bilirubin <= 1.5 x ULN.

• Gilbert's Syndrome may have a Bilirubin > 1.5 x ULN; aPTT, PT, not to exceed 1.2 x ULN.

• Adequate bone marrow (BM) independent of any growth factor support (with the exception of subjects with BM heavily infiltrated with underlying disease [80% or more] who may use growth factor support to achieve adequate BM) at Screening as follows:

• ANC >= 1000/µL;

• Platelets >= 75,000/mm3 (entry platelet count must be independent of transfusion within 14 days of Screening);

• Hemoglobin >= 9.0 g/dL.

• History of autologous BM transplant must be > 6 mos post transplant (prior to the 1st dose of study drug) & have adequate BM independent of any growth factor support (with the exception of subjects with BM that is heavily infiltrated with underlying disease [80% or more] who may use growth factor support to achieve adequate BM) at Screening as follows:

• ANC >= 1500/µL;

• Platelets >= 125,000/mm3;

• Hemoglobin >= 10.0 g/dL.

• Female subjects must be surgically sterile, postmenopausal (at least 1 year), or have negative results on a pregnancy test.

• All female subjects not surgically sterile or postmenopausal (at least 1 year) & non-vasectomized male subjects must practice birth control.

Exclusion Criteria:

• History/clinically suspicious for cancer-related CNS disease.

• Undergone allogeneic stem cell transplant.

• Undergone autologous stem cell transplant w/i 6 mos prior to 1st dose.

• History/predisposing condition of bleeding or currently exhibits signs of bleeding.

• Recent history of non-chemotherapy induced thrombocytopenic associated bleeding w/i 6 mos prior to 1st dose.

• Active peptic ulcer disease or other hemorrhagic esophagitis/gastritis.

• Active immune thrombocytopenic purpura or history of being refractory to platelet transfusions w/i 1 yr prior to 1st dose.

• Currently receiving/requires anticoagulation therapy or any drugs or herbal supplements that affect platelet function, with the exception of low-dose anticoagulation medications used to maintain the patency of a central IV catheter.

• Significant history of cardiovascular disease, renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, or hepatic disease.

• Positive for HIV, Hepatitis B, or Hepatitis C.

• Previous or current malignancies w/i the last 3 yrs:

• except adequately treated in situ carcinoma of the cervix uteri;

• basal or squamous cell carcinoma;

• in situ carcinoma of the bladder;

• or previous malignancy confined and surgically resected with curative intent.

• Has Prolymphocytic leukemia or Richter's transformation to an aggressive B-cell malignancy.

• Exhibits evidence of other clinically significant uncontrolled condition(s) including, but not limited to uncontrolled systemic infection or diagnosis of fever and neutropenia w/i 1 week prior to study drug.

• Prior exposure to ABT-263.

• Received antibody therapy w/i 30 days prior to 1st dose.

• Received any anti-cancer therapy including chemotherapy, immunotherapy, radiotherapy, hormonal, or any investigational therapy w/i 14 days prior to the 1st dose, or has not recovered to <Gr2 clinically significant AE(s) /toxicity(s) of the previous therapy.

• Received steroid therapy for anti-neoplastic intent, w/i 7 days prior to the 1st dose with the exception of inhaled steroids for asthma, topical steroids, or replacement/stress corticosteroids.

• Received aspirin w/i 7 days prior to the 1st dose.

• Consumed grapefruit or grapefruit products w/i 3 days prior to 1st dose.

• Females pregnant or breast-feeding.

Study Design

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• B-cell Chronic Lymphocytic Leukemia
• Leukemia
• Leukemia, Lymphocytic, Chronic, B-Cell
• Leukemia, Lymphoid

Intervention

Drug:
• ABT-263
Continuous dosing until disease progression using one of the following formulations: 25 mg/mL oral solution OR 50 mg/mL oral solution OR 2.0 grams/bottle powder for oral solution of 25 mg/mL when mixed OR 2.0 grams/bottle powder for oral solution of 50 mg/mL when mixed

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Abbott	Genentech, Inc.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Assess the safety of ABT-263 by evaluating study drug exposure, adverse events, serious adverse events, all deaths, as well as changes in laboratory determinations and vital sign parameters.		monthly (at a minimum)	Yes
Primary	Assess the objective response rate (partial response [PR] and confirmed complete response [CR]) of B-cell CLL subjects treated with ABT-263.		Every 3 months	No
Secondary	Assess the effects of ABT-263 on duration of overall response, PFS and overall survival in subjects with B-cell CLL.		Every 3 months	No
Secondary	Assess the effects of ABT-263 on time to response, 12-month survival rate, time to disease progression (TTP), and disease control rate in subjects with B-cell CLL .		Every 3 months	No
Secondary	Investigate the effects of ABT-263 on quality of life (FACT-Leu and EQ-5D), ECOG performance status, and biomarkers in subject with B-cell CLL.		Every 3 months	No